Advanced Proteome Therapeutics and Heidelberg Pharma Progress Collaborative Program

VANCOUVER, BC and LADENBURG, GERMANY—(Marketwired – January 08, 2018) – Advanced Proteome Therapeutics Corporation (APC), a therapeutics discovery and development company, and Heidelberg Pharma announced today advances in their collaborative activities. The companies have agreed to test the combination of APC's proprietary site–selective protein modification technology and Heidelberg Pharma's proprietary ATAC technology in order to generate superior cancer therapeutics.

Since the inception of the partnership, activities have been centered on antibody–amanitin conjugates that are produced using controlled conjugation methods and possess high target–specific cytotoxic potency. The companies have successfully demonstrated the generation of ATACs using APC's proprietary protein modification technology.

“In a first step, we have succeeded in producing ADCs that are sufficiently cytotoxic to target–expressing cancer cell lines to proceed to the next level of in vivo testing. Results obtained from this collaboration will help us to increase the efficacy of our ATACs”, commented Professor Andreas Pahl, CSO of Heidelberg Pharma.

“We are delighted that the partnership with Heidelberg Pharma has generated positive results and look forward to continuing our work together, to the benefit of both companies”, commented Randal Chase, CEO of Advanced Proteome Therapeutics.

APC's technology aims at the coupling of a cytotoxic payload site–selectively to an antibody of interest without the necessity of genetically engineering such antibody. This may lead to more homogeneous products with certain additional advantages such as an increase in stability in the circulation, fewer side effects and facilitating further pre–clinical and clinical drug development.

About Advanced Proteome Therapeutics

Advanced Proteome Therapeutics Corporation (APC) (TSX VENTURE: APC) (FRANKFURT: 0E8) is developing a proprietary technology to directly target cancerous tumors and avoid destroying normal cells. This type of agent is capable of greater potency, higher specificity, and lower toxicity than other therapies that can also attack healthy cells. Advanced Proteome is working to streamline the process by which these agents are prepared, which to date, has been extremely cumbersome, limiting their potential. www.advancedproteome.com

About Heidelberg Pharma

Heidelberg Pharma AG is a biopharmaceutical company based in Ladenburg, Germany. Heidelberg Pharma is an oncology specialist and the first company to develop the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology and to advance the biological mode of action of the toxin as a novel therapeutic principle. This proprietary technology platform is being applied to develop the Company's proprietary therapeutic ATACs as well as in third–party collaborations to create a variety of ATAC candidates. The proprietary lead candidate HDP–101 is a BCMA ATAC for multiple myeloma. The Company has entered into partnerships to further develop and commercialize its clinical assets MESUPRON® and REDECTANE®, while RENCAREX® is available for out–licensing and further development. Heidelberg Pharma AG is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol WL6. More information is available at www.heidelberg–pharma.com.

Heidelberg Pharma

Heidelberg Pharma AG

Sylvia Wimmer

Tel.: +49 89 41 31 38–29

Email: investors[at]hdpharma.com

Schriesheimer Str. 101, 68526 Ladenburg
Germany
IR/PR support

MC Services AG

Katja Arnold (CIRO)

Managing Director & Partner

Tel.: +49 89–210 228–40

Email: katja.arnold[at]mc–services.eu

Heidelberg Pharma Research GmbH

Business Development

Dr. Marcel Linssen
CBO, Executive Vice President

Tel.: +49 6203 1009–40

Email: m.linssen[at]hdpharma.com

 

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This communication contains certain forward–looking statements relating to the Company's business, which can be identified by the use of forward–looking terminology such as “estimates”, “believes”, “expects”, “may”, “will”, “should”, “future”, “potential” or similar expressions or by a general discussion of the Company's strategies, plans or intentions. Such forward–looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial position, earnings, achievements, or industry results, to be materially different from any future results, earnings or achievements expressed or implied by such forward–looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward–looking statements. We disclaim any obligation to update any such forward–looking statements to reflect future events or developments.

Comments are closed

RSS Daily Times Nigeria

  • NGO donates improved seedlings to 50, other items to 340 IDPs in Plateau
    The Justice Development and Peace Commission (JDPC), of the Catholic Archdiocese of Jos, on Saturday donated improved seedlings to 50 Internally Displaced Persons (IDPs) at Ban, Barkin Ladi Local Government Area (LGA), of Plateau. Presenting the seedlings, Rev. Fr. Polycarp Gana, the Assistant Coordinator of the NGO, said the gesture was aimed at alleviating the […]
  • FRSC doctorates 25 newly promoted officers in Nsukka
    The Federal Road Safety Commission (FRSC) on Saturday decorated 25 newly promoted officers in Nsukka Unit Command. READ ALSO: FRSC decorates 24 newly promoted officers in Badagry Mr Kalu Ogbonnaya, the Enugu State Sector Commander of FRSC, at the decoration ceremony in Enugu, congratulated the officers and urged them to be more committed to their […]
  • Africa has potential to be biggest economic miracle, says AfDB President
    Dr Akinwunmi Adesina, President,  African Development Bank (AfDB) on Saturday said Africa had the potential of becoming the biggest economic hub with the right policies and investments. Adesina made the assertion at the Inspiration Conference 2020 of the Redeemer’s Men Fellowship (Lagos Regions) in Lagos.The News Agency of Nigeria reports that the conference had as […]
  • Kaigama tasks Gov Lalong on inclusive governance
    The Catholic Apostolic Administrator of Jos, Arch Bishop Ignatius Kaigama, has urged Gov. Simon Lalong of Plateau, to ensure an all-inclusive governance in order to foster peace in the state. Kaigama made the call on Saturday in Jos, at the award of the Knight of St Gregory the Great, to Lalong, as directed by the […]

Weather for Abuja

[forecast]

RSS Vanguard News

  • Lassa fever: 29 deaths, 195 confirmed cases reported in 11 states — NCDC
    The Nigeria Centre for Disease Control (NCDC) has disclosed that 29 deaths and 195 confirmed cases of Lassa fever had been reported in 11 states of the federation. The post Lassa fever: 29 deaths, 195 confirmed cases reported in 11 states — NCDC appeared first on Vanguard News.
  • Impeachment: Trump lawyers prepare to deliver defence in Senate
    Donald Trump’s lawyers prepared to deliver his first full-throated defence Saturday in the Senate’s historic impeachment trial after Democratic prosecutors spent three days making their case for the United States president’s removal from office. Capping 24 total hours of arguments, Democrats told the 100 senators that Trump abused the power of the presidency in pressuringRead […]
  • Police arrest Abuja monarch, secretary over cop’s murder
    …CP condemns barbaric act, vows to fish out other culprits. By Kingsley Omonobi – Abuja. Following the murder of a senior Police Officer, ASP Eric Isaiah and one Moses Emmanuel over land dispute by persons mobilised by the traditional ruler of Ushafa community, Alhaji Mohammed Baba and his secretary, Danlami Busa in Abuja, and injuriesRead […]

© 2020 Nigeria Newsline. All Rights Reserved. Log in -